SEATTLE, WA, Jan 6, 2025 – (ACN Newswire) – Spectral Capital Corporation (OTCQB: FCCN), a pioneer in Quantum as a Service (QaaS) computing and decentralized cloud infrastructure, is pleased to announce the achievement of a major patent milestone as the first step in its plan to become a globally competitive leader in quantum computing patents.
"According to the World Intellectual Property Organization ("WIPO"), there were 350,000 patents filed worldwide in classical computing. An
Back to media releases (https://norgine.com/media)
Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i
As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the University of Rostock are taking water samples in all weathers. The aim is to use innovative approaches to improve wastewater treatment in Europe.
The Warnow seems to be flowing uphill on this cold morning, but it is only the wind that pushes the surface in strong gusts against the direction of flow. This part of the Warnow lies in a nature reserve. The reeds along its banks are home to valuable fa
ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) – EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to 15% of revenue, more than 46,000 employees worldwide.
– Increasingly challenging market environment for the direct-to-market segments
– Strong growth in the Semiconductor Manufacturing Technology segment
– Ou
– Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases.
– The EC approval follows a positive opinion issued on 19 October 2024 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenst
Lissi GmbH has qualified for the final phase of the EUDI-Wallet prototype competition organised by the German Federal Agency for Leap Innovation (SPRIND). The competition promotes innovative solutions for the implementation of the European eIDAS 2.0 regulation.
“We are proud to have once again convinced the jury and to be part of such a prestigious programme. We would like to express our gratitude to the Federal Ministry of the Interior and Community and SPRIND for the professional and t
The akenza IoT platform announces the launch of akenza Building Edge, a powerful solution that bridges Building Management Systems (BMS) and the IoT, enabling intelligent, efficient, and sustainable building operations.
Individual newsroom, exclusive event press box and SEO booster: PresseBox offers LogiMAT exhibitors customised PR and SEO support for a successful trade fair
Our photographer Anas Alkharboutli, who documented the civil war in Syria in a unique visual language, has been killed in an airstrike near the Syrian city of Hama. Anas was just 32 years old.The hope for a better future lives on in his photography.
Anas Alkharboutli joined dpa as a photographer in the Middle East in 2017. He reported primarily from the Syrian civil war zone. In the past few days, his pictures have been seen around the world, as Anas was reporting on the new flare-up of the ci
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/uploads/716035.jpg "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma")
